The Fly | DRUG

Tuesday

One new option listing on July 7th

DRUG

Jul 7, 8:30 AM

Over a week ago

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

May 21, 11:26 AM

Bright Minds price target raised by $30 at Piper Sandler, here's why

DRUG

May 20, 6:44 AM

Psychedelic: Clearmind's CMND-100 meets primary endpoint in trial

Apr 16, 11:20 AM

Bright Minds initiated with bullish view at Jefferies, here's why

DRUG

Apr 12, 7:16 PM

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

Mar 5, 10:14 AM

Bright Minds price target raised by $30 at H.C. Wainwright, here's why

DRUG

Mar 4, 8:31 AM

Bright Minds price target lowered by $16 at Baird, here's why

DRUG

Feb 13, 9:15 AM

Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial

Jan 8, 10:57 AM

Bright Minds 1.945M share Secondary priced at $90.00

DRUG

Jan 8, 6:25 AM

Bright Minds price target raised by $60 at Baird, here's why

DRUG

Jan 7, 7:56 AM

Bright Minds price target raised by $75 at BTIG, here's why

DRUG

Jan 7, 6:42 AM

Bright Minds announces $100M common shares offering

DRUG

Jan 6, 4:06 PM

Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101

DRUG

Jan 6, 7:22 AM

Bright Minds price target raised by $7 at Baird, here's why

DRUG

Nov 7, 7:23 AM

Psychedelic: Compass Pathways, GH Research report Q3 earnings

Nov 6, 11:33 AM

Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study

Sep 11, 10:43 AM

Bright Minds initiated with bullish view at BTIG, here's why

DRUG

Sep 8, 5:54 AM

Psychedelic: Bright Minds reports preclinical BMB-201 results

Sep 4, 11:04 AM

Bright Minds says BMB-201 outperforms sumatriptan in preclinical model

DRUG

Sep 4, 8:33 AM

Psychedelic: atai Life Sciences, Cybin report earnings results

Aug 14, 11:25 AM

No more stories

Precision Drug Design & Receptor Targeting: Bright Minds focuses on developing novel, proprietary compounds specifically designed to modulate serotonin receptors (e.g., 5-HT2A, 5-HT2C) with high selectivity, aiming for improved therapeutic profiles, reduced side effects, and shorter duration of action compared to classical psychedelics.

Robust & Diversified Pipeline: The company boasts a broad pipeline of drug candidates addressing multiple significant neurological and psychiatric disorders, including epilepsy, pain, depression, anxiety, and cluster headache, diversifying risk and expanding potential market reach.

Strong Intellectual Property Portfolio: Bright Minds focuses on developing novel chemical entities, which allows for the creation and protection of a robust intellectual property portfolio through patents, securing exclusivity for their innovative therapeutic compounds.

Clinical Trial Outcomes Risk: The success of Bright Minds' drug candidates is subject to the unpredictable outcomes of preclinical and clinical trials, with potential for costly failures at any stage.

Regulatory Approval Uncertainty: Gaining necessary approvals from health authorities like the FDA or EMA for their drug candidates is a lengthy, costly, and uncertain process with no guarantee of success.

Significant Capital Requirements: The company requires substantial ongoing financing to fund research, development, and clinical trials, and there is no guarantee it will be able to raise sufficient capital on favorable terms.